Feature | October 10, 2013

Rare Fetal Cardiac Procedure Performed for First Time in Southern California

Specialists collaborate on aortic valvuloplasty on 25-week-old fetus

cardiovascular ultrasound structural heart valve repair hollywood presbyterian

A team of doctors at CHLA-USC Institute of Maternal-Fetal Health at CHA Hollywood Presbyterian Medical Center perform first fetal aortic valvuloplasty in utero in Southern California September 25

October 10, 2013 — A mother and her 25-week-old fetus are doing well after a team of physicians performed a successful in utero cardiac interventional procedure on the fetus at California Hospital Assn. (CHA) Hollywood Presbyterian Medical Center.

The minimally invasive procedure, known as a fetal aortic valvuloplasty, was a first for a Southern California hospital. Doctors succeeded in using a tiny balloon to open the fetus’s narrow aortic valve in order to increase blood flow to the body, improve left heart function and promote normal left heart growth during the critical third trimester growing stage.

Ramen Chmait, M.D., and Frank Ing, M.D., performed the procedure on Sept. 25 at Children’s Hospital Los Angeles. Collaborating for the first time, both physicians had performed the delicate fetal procedure before at hospitals outside of California.

“The surgery went beautifully; we were able to open up the aortic valve,” said Ing. “Fetal cardiac intervention is a relatively new field and requires expertise, commitment and collaboration among four specialty areas: pediatric interventional cardiology, fetal echocardiography, maternal-fetal-medicine and anesthesia.”

The patient, a 28-year-old Sylmar, Calif., mother of two, was 25 weeks pregnant at the time of procedure, which took a total of three hours and involved a team of 12, including physicians and support staff. Much of that time was devoted to Chmait’s maneuvering the fetus into position by manually adjusting the mother’s abdomen. With the assistance of a detailed ultrasound imaging by Children’s Hospital fetal cardiologist Jay Pruetz, M.D., Chmait inserted a special needle into the womb, through the fetal chest and into the peanut-sized heart’s left ventricle, positioning it below the aortic valve. As Chmait steadied the needle, Ing used Chmait’s hand as a platform for his hand to thread a hair-thin wire through the needle and out the tip, positioning the wire across the fetus’s aortic valve. The wire was then used as a rail for Ing to maneuver a tiny balloon-tipped catheter into position across the valve. Ing carefully inflated the balloon, which inflated to open the valve and increase blood flow into the aorta. The balloon, wire and needle were then removed.

The time from actual needle insertion to the balloon opening took roughly 15 minutes, Ing says. The mother was sedated during the procedure.

The fetal aortic valvuloplasty procedure has been completed more than 100 times in the United States., with most taking place at Boston Children’s Hospital. Only a handful of hospitals west of the Mississippi River have performed the procedure.

For more information: www.losangelesfetaltherapy.org, www.hollywoodpresbyterian.com

Related Content

ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Scientists Discover New Type of Immune Cells Essential for Forming Heart Valves

Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed. Image courtesy of Developmental Cell/UCLA Broad Stem Cell Research Center.

News | Heart Valve Technology | March 06, 2019
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the...
Global Market for Transcatheter Treatments to Double in Next Five Years
News | Heart Valve Technology | March 01, 2019
When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter...
FDA Approves IDE Study for Foldax Biopolymer Heart Valve Platform
News | Heart Valve Technology | February 18, 2019
Foldax Inc. announced the U.S. Food and Drug Administration (FDA) has granted investigative device exemption (IDE)...
Thubrikar Announces First-in-Human Implant of Optimum TAVI System
News | Heart Valve Technology | January 29, 2019
Thubrikar Aortic Valve Inc. announced the first human implant of the Optimum TAV using their transcatheter aortic valve...
Perceval Valve Offers Performance, Economic Advantages in Aortic Disease Treatment
News | Heart Valve Technology | January 29, 2019
LivaNova PLC announced the publication of three separate studies highlighting the performance of its sutureless aortic...
First Tendyne Transcatheter Mitral Valve Implanted in New York
News | Heart Valve Technology | January 28, 2019
Lenox Hill Hospital is the first hospital in New York City to successfully implant Abbott’s Tendyne transcatheter...
Overlay Init